ZBD | $40,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026)
Certified by Founder
Lodge
Sionna Therapeutics
start up
United States
- Boston, MA
- 07/03/2024
- Series C
- $182,000,000
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
- Industry Biotechnology
- Website https://www.sionnatx.com/
- LinkedIn https://www.linkedin.com/company/sionna-therapeutics/
Cubby | $63,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Cork Protocol | $5,500,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)
Mendra | $82,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
Antidote Legal | $5,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)